Clinical observation of Nalaxon in the treatment of chronic obstructive pumlonary disease and type II chronic respiratory failure

Objective: To investigate the treatment effect of Nalaxon in the treatment of chronic obstructive pumlonary disease(COPD) and type Ⅱ chronic respiratory failure.Methods: 120 cases of COPD patients with type Ⅱ chronic respiratory failure were randomly divided into treatment group and control group.On the basis of routine treatment,patients in the therapy group were additionally given Naloxone 0.8 mg with 5% glucose 20 ml injecta through vein and 1.2 mg Naloxone with 250 ml glucose intravenous drip with the speed of 0.4-0.8 mg/h,5 days as a course.At the same time,the control group were additionally given Nikethamide 1.875～3.75 g with 250-500 ml 5% glucose injecta through vein,7 days as a course.Results: There was no significant difference in blood gas between two groups before treatment(P0.05).The PaO2 of therapy group [(89.21±11.46)mm Hg] was significantly higher than that of control group [(67.13±13.53)mm Hg](t=9.38,P0.01).Meanwhile,the PaCO2 of treatment group [(36.29±14.09)mm Hg] was obviously lower than that of control group [(57.63±13.82)mm Hg](t=8.928,P0.01).The total efficacy of treatment group(86.67%) was obviously higher than control group(58.33%) which show statistic significance(χ2=7.936,P0.01).Conclusion: Naloxone shows obvious advantages of safe,efficient,good tolerance in treatment of COPD combined with type Ⅱ chronic respiratory failure which can be recognized as a prior choice in the treatment.